Authors
Latest:
Dr. Ghia on the Key Takeaways of the CAPTIVATE Study in Treatment-Naïve CLLPaolo Ghia, MD, PhD, discusses the key takeaways of the phase 2 CAPTIVATE study in chronic lymphocytic leukemia.
Latest:
Dr Roy on Limitations of the Pathway Trial Evaluating PGS and Survival in Breast CancerArya Mariam Roy, MBBS discusses limitations of the Pathway trial evaluating the association between polygenic scores and survival outcomes in patients with breast cancer.
Latest:
Dr. Hecht on the Investigation of XL092/Atezolizumab in MSS/MSI-L mCRCJ. Randolph (Randy) Hecht, MD, discusses the investigation of XL092 plus atezolizumab in patients with microsatellite stable/microsatellite instability–low metastatic colorectal cancer.
Latest:
Dr. Ko on Unmet Needs in PD-L1–Negative TNBCHeidi Ko, DO, discusses unmet needs in patients with PD-L1–negative triple negative breast cancer.
Latest:
Dr. Dhakal on the Evolution of Pertuzumab Regimens in HER2+ Breast CancerAjay Dhakal, MBBS, discusses the two key trials supporting the use of pertuzumab as a standard-of-care regimen in HER2-positive breast cancer.
Latest:
Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and TreatmentLearn more about the epidemiology, diagnosis, and treatment of advanced systemic mastocytosis in this summary from an expert multidisciplinary case-based discussion.
Latest:
Dr Damodaran on Futibatinib Plus Fulvestrant in FGFR1-Amplified HR+/HER2– Breast CancerSenthil Damodaran, MD, PhD, discusses the efficacy of futibatinib plus fulvestrant in patients with FGFR1-amplified metastatic hormone receptor–positive, HER2-negative breast cancer according to findings from the phase 2 FOENIX-MBC2 trial.
Latest:
Dr Pollyea on the Mechanism of Revumenib in KMT2A-Rearranged R/R AMLDan Pollyea, MD, MS, discusses the mechanism of action for the menin inhibitor revumenib in KMT2A-rearranged relapsed/refractory acute myeloid leukemia.
Latest:
Dr Siegel on the Use of Carfilzomib/Iberdomide/Dexamethasone Therapy in Multiple MyelomaDavid Samuel Dicapua Siegel, MD, discusses the potential use of carfilzomib, iberdomide, and dexamethasone in newly diagnosed multiple myeloma.
Latest:
Investigators Seek to Resolve the “Obesity Paradox” in Lung CancerSmoking is associated with the most widely known cancer causing carcinogen across the world. However, a second, more insidious factor has been increasingly recognized for its role in promoting cancer growth: obesity.
Latest:
Dr O’Brien on Advances in Molecular Imaging in ER+ Breast CancerSophia R. O'Brien, MD, discusses recent advances in the diagnosis and staging of estrogen receptor–positive metastatic breast cancer.
Latest:
Dr Reshef on Data From the BMT CTN 1703 Trial Evaluating Post-Transplant GVHD Prophylactic RegimensRan Reshef, MD, discusses findings from the phase 3 BMT CTN 1703 trial examining graft-vs-host disease prophylaxis in reduced intensity conditioning.
Latest:
Emerging role of doublet triplet therapies in R/R CLL: Expert PerspectivesPanelists discuss how they balance the potential benefits of aggressive first-line treatment in chronic lymphocytic leukemia against the importance of preserving effective options for subsequent lines of therapy, considering factors such as patient prognosis, treatment goals, and the evolving landscape of available therapies.
Latest:
Dr Gopal on a Case Study of a Patient With Bladder CancerNikhil Gopal, MD, discusses details from a case discussion of a patient with bladder cancer.
Latest:
Dr. Kim on Clinical Implications of ADCs in HER2+ Solid TumorsEdward S. Kim, MD, MBA, discusses the clinical implications of antibody-drug conjugates in HER2-positive solid tumors.
Latest:
Dr. Schenk on the Importance of Investigating Novel Targets in Lung CancerErin Schenk, MD, PhD, discusses the importance of investigating novel targets and pathways in lung cancer.
Latest:
$10.8M Initiative Unites Engineering and Health Researchers to Improve Cancer TreatmentsA University of Arizona project, with funding from the state's New Economy Initiative, creates humanlike cancer models and growth environments to help improve prevention, diagnosis and treatment.
Latest:
Dr Pobel on the Prognostic Value of Phenotypic and Genomic Characterization in De Novo mCSPCCedric Pobel, MD, discusses the potential prognostic value of phenotypic and genomic characterization of de novo mCSPC from the phase 3 PEACE-1 trial.
Latest:
Freeman on Mortality Differences Across Racial Groups in Male Patients With Breast CancerJason Jincong Freeman, discusses mortality differences across various racial groups in male patients with stage I, II, or III breast cancer.
Latest:
Dr. Puechl on Choosing Between PARP Inhibitors in Ovarian CancerAllison M. Puechl, MD, discusses choosing between PARP inhibitors in ovarian cancer.
Latest:
Dr Hafez on the Design of the FeDeriCa Trial in HER2+ Early Breast CancerMaria Hafez, MD, discusses the design of, and outcomes from, the phase 3 FeDeriCa trial in patients with HER2-positive early breast cancer.
Latest:
Dr. Pianko on the Role of Daratumumab in Frontline MyelomaMatthew James Pianko, MD, discusses the role of daratumumab in the frontline treatment of multiple myeloma.
Latest:
Dr Sammons on the Investigation of Brain Metastases in HER2+ Breast CancerSarah Sammons, MD, discusses the rationale for examining brain metastases in HER2-positive breast cancer, highlighting the implications of recent data.
Latest:
Future Directions With PSMA Ligand–Directed TherapiesHighlights of potential future applications of PSMA ligand–directed therapies in prostate cancer.
Latest:
Dr. D’Angelo on Emerging Therapies in DLBCLChristopher R. D’Angelo, MD, discusses emerging therapies in diffuse large B-cell lymphoma.
Latest:
Audience Q&A: Emerging Therapeutic Targets in Advanced NSCLCClosing out their discussion on the treatment paradigm of advanced NSCLC, key opinion leaders review emerging targets and ongoing clinical trials.
Latest:
Dr. Huang on Research in ALK+ NSCLCChao H. Huang, MD, FACP, discusses ongoing research around the use of ALK inhibitors for non–small cell lung cancer.
Latest:
Dr. Baron on Contributing Factors for Developing Breast CancerPaul Lawrence Baron, MD, discusses contributing factors for developing breast cancer.
Latest:
Future Perspectives on the Treatment of Desmoid TumorsA panel of oncology experts provides insights into the future outlook for desmoid tumor treatment, discussing anticipated developments in the field.
Latest:
Dr Murray on the Investigation of Prognostic Markers in Cemiplimab-treated NSCLCJoseph Christopher Murray, MD, PhD, discusses the investigation of peripheral myeloid cells as prognostic markers in patients with non–small cell lung cancer treated with cemiplimab.
.jpg?fit=crop&auto=format)
